(Q34020878)

English

Soluble human epidermal growth factor receptor 2 (HER2) levels in patients with HER2-positive breast cancer receiving chemotherapy with or without trastuzumab: results from North Central Cancer Treatment Group adjuvant trial N9831

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23744760%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

Soluble human epidermal growth factor receptor 2 (HER2) levels in patients with HER2-positive breast cancer receiving chemotherapy with or without trastuzumab: results from North Central Cancer Treatment Group adjuvant trial N9831 (English)

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23744760%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

1 reference

based on heuristic

inferred from title

Erb-b2 receptor tyrosine kinase 2

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

13

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23744760%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

14

object named as

Edith A Perez

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23744760%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

10

object named as

Wilma L Lingle

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23744760%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

author name string

Alvaro Moreno-Aspitia

1

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23744760%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

David W Hillman

2

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23744760%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

Stephen H Dyar

3

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23744760%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

Kathleen S Tenner

4

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23744760%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

Julie Gralow

5

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23744760%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

Peter A Kaufman

6

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23744760%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

Nancy E Davidson

7

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23744760%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

Jacqueline M Lafky

8

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23744760%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

Monica M Reinholz

9

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23744760%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

Leila A Kutteh

11

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23744760%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

Walter P Carney

12

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23744760%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

language of work or name

0 references

publication date

6 June 2013

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23744760%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

number of pages

8

1 reference

based on heuristic

inferred from page(s)

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23744760%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

119

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23744760%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

15

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23744760%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

2675-2682

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23744760%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

Predictive value of HER2 serum levels in patients treated with lapatinib or trastuzumab -- a translational project in the neoadjuvant GeparQuinto trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4126833

28 July 2018

Sequential versus concurrent trastuzumab in adjuvant chemotherapy for breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4126833

28 July 2018

Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4126833

28 July 2018

Topoisomerase II{alpha} amplification does not predict benefit from dose-intense cyclophosphamide, doxorubicin, and fluorouracil therapy in HER2-amplified early breast cancer: results of CALGB 8541/150013

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4126833

28 July 2018

Utility of serum HER2 extracellular domain assessment in clinical decision making: pooled analysis of four trials of trastuzumab in metastatic breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4126833

28 July 2018

HER-2 and topoisomerase II as predictors of response to chemotherapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4126833

28 July 2018

Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4126833

28 July 2018

American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4126833

28 July 2018

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4126833

28 July 2018

Prognostic and predictive factors in early-stage breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4126833

28 July 2018

Potential Clinical Utility of Serum HER-2/neu Oncoprotein Concentrations in Patients with Breast Cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4126833

28 July 2018

Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4126833

28 July 2018

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4126833

28 July 2018

ELISA for quantitation of the extracellular domain of p185HER2 in biological fluids

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4126833

28 July 2018

Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28130

21 January 2018

Two concurrent phase II trials of paclitaxel/carboplatin/trastuzumab (weekly or every-3-week schedule) as first-line therapy in women with HER2-overexpressing metastatic breast cancer: NCCTG study 983252.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28130

21 January 2018

Human epidermal growth factor receptor 2 (HER2) extracellular domain levels are associated with progression-free survival in patients with HER2-positive metastatic breast cancer receiving lapatinib monotherapy.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28130

21 January 2018

Evaluation of serum HER2 extracellular domain in early breast cancer patients: correlation with clinicopathological parameters and survival

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28130

21 January 2018

Topoisomerase II{alpha} amplification and anthracycline-based chemotherapy: the jury is still out.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28130

21 January 2018

C-MYC alterations and association with patient outcome in early-stage HER2-positive breast cancer from the north central cancer treatment group N9831 adjuvant trastuzumab trial.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28130

21 January 2018

Insulin-like growth factor receptor (IGF-1R) in breast cancer subtypes.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28130

21 January 2018

Circulating HER-2/erbB-2/c-neu (HER-2) extracellular domain as a prognostic factor in patients with metastatic breast cancer: Cancer and Leukemia Group B Study 8662.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4126833

29 October 2018

Automated assay for HER-2/neu in serum

1 reference

https://pubmed.ncbi.nlm.nih.gov/23744760

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/23744760

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cleavage of the HER2 ectodomain is a pervanadate-activable process that is inhibited by the tissue inhibitor of metalloproteases-1 in breast cancer cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/23744760

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Changes over time of extracellular domain of HER2 (ECD/HER2) serum levels have prognostic value in metastatic breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/23744760

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Monitoring serum HER2 levels during neoadjuvant trastuzumab treatment within the GeparQuattro trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/23744760

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1002/CNCR.28130

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23744760%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23744760%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23744760%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34020878&oldid=1773465806"